Circulating transferrin receptor has been detected in human serum with a sensitive immunoassay. The mean concentrations of the serum transferrin receptor in healthy males and females were 251 +/- 94 (mean +/- SD) ng/ml and 256 +/- 99 ng/ml, respectively. The serum receptor concentration in patients with haematological malignancies, including acute leukaemia, multiple myeloma and malignant lymphoma, varied widely, from normal to 1100 ng/ml. A single band with an approximate molecular weight between 80,000 and 100,000 daltons was obtained by polyacrylamide gel electrophoresis-immunoblotting analysis of serum.

Serum transferrin receptors were measured by a sandwich radioimmunoassay procedure in patients with iron deficiency anemia, autoimmune hemolytic anemia and aplastic anemia. The mean circulating transferrin receptor concentration of normal subjects and patients with iron deficiency anemia, autoimmune hemolytic anemia and aplastic anemia are 253 +/- 82 ng/mL, 730 +/- 391 ng/mL, 1,426 +/- 1,079 ng/mL, and 182 +/- 39 ng/mL, respectively. The values for those with iron deficiency anemia and autoimmune hemolytic anemia were significantly higher than that of normal controls and the values for those with aplastic anemia were lower than that of normal controls. After iron supplementation in iron deficiency anemia, the serum transferrin receptor values increased twofold over those of pretreatment values. This increase parallels an increase in peripheral reticulocytes. Therefore, the number of circulating transferrin receptors in anemic patients may reflect the level of bone marrow erythropoiesis and is a potentially useful new index for red cell production.

Rat peritoneal macrophages are capable, in vitro, of processing and releasing iron derived from phagocytosed, immunosensitized red cells. From 20% to 60% of the red cell iron can be returned to the culture medium in 24 h, with resident macrophages more active than inflammatory, peptone-induced macrophages. When apotransferrin is present in the culture medium, from 39% to 72% of iron released from macrophages is bound to the protein, with most of the remainder in a ferritin-like form. No distinct preference of released iron for either site of transferrin could be observed. The absence of apotransferrin depresses iron release only slightly, with much of the iron then released in a form readily available to the protein in vitro. Pronase treatment of macrophages, which abolishes their ability to bind transferrin, depresses iron release no more than 10-15%. It appears, therefore, that binding of apotransferrin to macrophages may not be essential for iron excretion by the cells.

The clinical significance of radioreceptor assay for transferrin receptors of human cancerous tissues was evaluated. Fresh surgical specimens from various carcinoma tissues were solubilized with 1% Triton X-100 and the extracts were mixed with '25I-labelled diferric transferrin. The free transferrin and the receptor-bound transferrin were separated by 15% polyethylene glycol precipitation. The % specific transferrin binding to gastric, colonic, lung and mammary carcinoma tissues ranged between 3.9 and 13.9%, whereas those for normal stomach and colon were less than 2%. The concentrations of transferrin receptors in these cancerous tissues ranged between 3.7 and 28.3 pmole/g tissues. It was concluded that the amounts of transferrin receptors were significantly increased in all of the tumor tissue extracts examind and may thereby provide a useful marker for the diagnosis of malignancies. transferrin receptor ; transferrin ; radioreceptor assay ; cell proliferationThe first event in cellular iron uptake is the binding of differric transferrin to its receptors (Aisen and Listowsky 1980). In addition to erythroid cells (Jandl and Katz 1963), transferrin receptors (Tf • R) have been found in established cell lines in vitro (Hamilton et al. 1979;Trowbridge and Omary 1981). Recently, Shindelman et al. (1981) and Habeshow and Lister (1983) have reported the presence of Tf.• R in the tissue of breast cancer and malignant lymphoma, respectively. Furthermore, it has become apparent that the Tf.• R are expressed in much greater amounts on malignant cells than on non-malignant cells, although a quantitative study is lacking. These findings have generated a considerable interest on Tf.• R which appear to be a marker of malignant transformation.In the present paper, we investigated Tf.• R in surgical specimens obtained from a variety of different types of human malignancy. The results of our study indicate that Tf•R may be useful as a marker of cell proliferation.